Android app on Google Play

Deutsche Bank Comments on Chelsea Therapeutics' (CHTP) Northera

February 14, 2014 3:50 PM EST Send to a Friend
Get Alerts CHTP Hot Sheet
Price: $4.73 --0%

Rating Summary:
    3 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade CHTP Now!
Join SI Premium – FREE
Deutsche Bank's Robyn Karnauskas made the following comments on Chelsea Therapeutics' (Nasdaq: CHTP).

"Northera's PDUFA data is scheduled for TODAY, we see FV of CHTP at $8-9/sh (80% upside potential) if approved and $.27 (95% downside) if not approved If approved, we model peak sales of Northera at ~$550M WW ($450M US and $100M ROW) assuming 50% market share," said Karnauskas.

"We could see FV at $8-9/sh after the approval assuming 10%-12.5% discount rate. If we assume 50% market share, we see FV at $12-$13/sh assuming 10-12.5% discount rate (peak sales ~$780M). If Northera is not approved we see the stock trading at cash or ~$0.27/ sh. This is calculated based on $21M in cash and ~76 M shares."

Deutsche Bank has a Hold rating on Chelsea Therapeutics (NASDAQ: CHTP) price target of $5.00

For an analyst ratings summary and ratings history on Chelsea Therapeutics click here. For more ratings news on Chelsea Therapeutics click here.

Shares of Chelsea Therapeutics closed at $4.94 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, FDA

Related Entities

Deutsche Bank

Add Your Comment